Back to search results

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance in Older Adults

This study is looking at how two different dietary supplements affect exercise tolerance in healthy adults aged 60 to 80. One supplement is a special blend called EGA®, which includes Nicotinamide Mononucleotide (NMN), betaine, and low-dose hydrogen peroxide. The other is a conventional NMN supplement. A third group will receive a placebo (an inactive substance that looks and tastes the same). Researchers want to see if these supplements can improve how long you can exercise before getting tired. To join, you need a doctor's clearance and good heart health. The study is currently unclear on its recruitment status.

Study design
This is a randomized, double-blind, placebo-controlled study with 40 participants. It uses a crossover design, meaning participants will try different treatments at different times.
What's involved
Participants will take a supplement twice daily for 4-week periods. Exercise tolerance will be measured at the beginning and end of each 4-week period.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07144527

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Recruiting
NAAges 60–80InterventionalBasic science
Scott Silveira
~40 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:NMN, betaine, low-dose hydrogen peroxide (EGA)Nicotinamide Mononucleotide (NMN)Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM).
Measured over Measured at the beginning and end of each 4-week intervention period.

Conditions

Aging
Frailty
Exercise Tolerance
Healthy Male and Female Subjects

Explore related trials

AgingFrailty

Where it's being run

1 sites across 1 states
California1

Who to contact

Nancy Castellanos, BA
[email protected]
310-666-6585
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 60 to 80 years, of any sex
Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing
Montreal Cognitive Assessment (MoCA) score of 26 or higher
Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation
Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling
Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications
Ability to attend at least four in-person laboratory visits in Beverly Hills, California
Non-smoker for at least 12 months
Able to provide informed consent and comply with study procedures
Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study

Exclusion

Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg)
Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)
Significant neurological impairments that hinder comprehension of instructions or participation in exercise
Terminal illness or conditions limiting life expectancy or ability to complete the study
Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions
Significant orthopedic limitations or injuries that prevent safe exercise participation
Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks
Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study
Current substance abuse affecting study participation or adherence
Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives
Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion
Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results

What this trial measures

  • Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM).Measured at the beginning and end of each 4-week intervention period.

    Duration (in seconds) that participants can sustain a constant submaximal workload on a cycle ergometer until volitional fatigue. This is a validated surrogate for submaximal exercise tolerance.